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ABSTRACT: The glycocalyx, a thick layer of carbohydrates, surrounds the cell wall of most
bacterial and parasitic pathogens. Recognition of these unique glycans by the human
immune system results in destruction of the invaders. To elicit a protective immune
response, polysaccharides either isolated from the bacterial cell surface or conjugated with a
carrier protein, for T-cell help, are administered. Conjugate vaccines based on isolated
carbohydrates currently protect millions of people against Streptococcus pneumoniae,
Haemophilus inf luenzae type b, and Neisseria meningitides infections. Active pharmaceutical
ingredients (APIs) are increasingly discovered by medicinal chemistry and synthetic in
origin, rather than isolated from natural sources. Converting vaccines from biologicals to
pharmaceuticals requires a fundamental understanding of how the human immune system
recognizes carbohydrates and could now be realized. To illustrate the chemistry-based
approach to vaccine discovery, I summarize efforts focusing on synthetic glycan-based
medicinal chemistry to understand the mammalian antiglycan immune response and define glycan epitopes for novel synthetic
glycoconjugate vaccines against Streptococcus pneumoniae, Clostridium dif f icile, Klebsiella pneumoniae, and other bacteria. The
chemical tools described here help us gain fundamental insights into how the human system recognizes carbohydrates and drive the
discovery of carbohydrate vaccines.
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1. INTRODUCTION
Humans have been living with and fighting infectious diseases
from the dawn ofmankind. Still today, infectious diseases caused
by bacteria, viruses, and parasites remain a major global health
problem as vividly illustrated by the COVID-19 pandemic. The
20th century saw breakthroughs in ways to curb and control
infectious diseases by fundamentally advancing two strategies. In
the first strategy, antibiotics, antiviral, and antiparasitic
medications were discovered to treat patients, and these
compounds helped to save many millions of lives each year. In
the second strategy, many vaccines were developed to protect
people against some of the most serious infectious diseases.
Vaccines prevent the formation of sequelae such as mental
retardation that used to result in immense health care
expenditures. Therefore, vaccination is the most cost-effective
means for society to save lives. Thanks to the advent of vaccines,
smallpocks and polio were almost eradicated in the 20th century.
Many deadly infections, such as those caused by tetanus that
repeatedly resulted in death after small injuries, are almost
entirely forgotten today.
At the beginning of the 21st century many “new” infectious
diseases such as corona viruses and drug resistant bacteria such
as Klebsiella pneumoniae are threatening us while diseases we
thought to have under control are re-emerging such as
Mycobacterium tuberculosis. After almost a century of using
effective antibiotics against most deadly bacterial infections,
antibiotic resistance and the evolution of multiresistant bacteria
that spread, particularly in hospital and long-term care settings,
have become a major problem. The need to develop effective
vaccines against many different infectious diseases caused by
viruses, parasites, and bacteria is more urgent today than at any
time since the development of the polio vaccine.1 With a greatly
improved understanding of the human immune system and
pathogen biology, the stage is set to create new vaccines to offer
protection from infectious diseases that have become resistant to
antibiotics. Synthetic chemistry is the enabling technology that
supports the creation of efficacious and affordable vaccines.
1.1. Pharmaceuticals and Biologicals
The development of the pain medication Aspirin is prototypical
for the process of drug discovery. Sumerian and Egyptian texts
dating back 5000 years describe the leaves of the willow tree as a
treatment for fever, inflammation, and aches. The active
pharmaceutical ingredient, acetylsalicylic acid, was first isolated
in 1828 by extracting the active ingredient from willow trees,
producing bitter tasting yellow crystals that were named salicin.
In 1853, treatment of sodium salicylate with acetyl chloride
produced acetylsalicylic acid.2 The chemical structure was
determined and more efficient syntheses were developed. The
first rigorous clinical trial of salicin in 1876 confirmed its effects
in reducing fever and joint inflammation in rheumatism patients.
In 1899, the Bayer Company registered the trade name Aspirin
for acetylsalicylic acid as a replacement for salicylate medicines.3
Thus, a plant extract, used as medication for thousands of years,
was replaced by a synthetic pharmaceutical after the active
pharmaceutical ingredient (API) was discovered and a synthesis
was developed.
Most medications used today are synthetic molecules of
defined composition. Regulatory agencies can implement strict
measures to ensure proper characterization by spectroscopic and
other means. The intellectual property is protected by
composition of matter claims to defend novel medications
from competition. Artemisinin combination therapies, the most
effective means of treating malaria, stand out among the few
major medications still derived by extraction. The natural
product artemisinin, extracted from sweet wormwood plants, is
converted to its artemether and artesunate derivatives, the major
APIs.4
Regulatory agencies go to great lengths to ensure that
marketed medications are pure, unadulterated, and exactly what
is claimed. These agencies also oversee the production of
vaccines that have not yet reached the same level of molecular
definition as pharmaceuticals. In 1796, the British doctor
Edward Jenner protected children from smallpox infections by
injecting them with cowpox he obtained by draining pus from
the cow blisters. Similar techniques had been practiced in China
and other countries already for centuries. Although using
children to test a medical hypothesis is utterly unthinkable
today, his experiment marked the birth of vaccines. Whole cell
vaccines were the first vaccines developed and consist of either
attenuated or killed organisms. Although whole cell vaccines
confer long-lasting immunity against infectious disease,
culturing pathogenic organisms in high quantities can be
difficult.5 In rare cases, attenuated pathogens might even cause
disease in immunocompromised individuals.6 Subunit vaccines,
often considered safer than whole cell vaccines, are preparations
of molecularly defined components of the target organisms that
cannot cause disease. The components can be proteins such as
secreted toxins that can be obtained by recombinant
expression,5 as well as virus-like particles or cell surface glycans.
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Due to the low immunogenicity of these antigens, subunit
vaccines are usually formulated with adjuvants.6
Proteins are the antigens of choice in subunit vaccines due to
their ability to induce an efficient immune response. However,
protein antigens may fail to protect from disease when they are
not exposed on the surface of a pathogen and therefore
inaccessible to the immune system. The variability of surface
proteins may prevent the buildup of a protective immunological
memory and surface proteins may be very similar to or derived
from cellular proteins of the host and hence may not be
sufficiently immunogenic. Carbohydrate-based vaccines present
an attractive alternative in these cases. Successful glycoconjugate
vaccines made from isolated capsular polysaccharides (CPS)
from bacteria as well as recombinantly expressed proteins
identified from gene sequences (“reverse vaccinology”) have
been developed.5
The logical end point in vaccine development, in analogy to
the evolution in pharmaceuticals, is fully synthetic vaccines
through which one or more synthetic antigens are administered.
Hence, synthetic molecules described by their composition of
matter would be used instead of biologicals defined by the
production process. Then, regulatory authorities could define
vaccine composition and purity based on physical character-
ization such as NMR spectroscopy and mass spectrometry; that
is, these standard criteria for the regulatory approval practice of
pharmaceuticals could be readily adopted to the vaccine field.
1.2. Carbohydrate Conjugate Vaccine Anatomy
Infection with pathogenic bacteria results in a potent immune
response that is generated by the molecular recognition of
proteins, lipids and carbohydrates. Proteins are thymus-
dependent antigens that can induce the formation of
immunological memory, while polysaccharide- or lipid-based
thymus-independent antigens cannot elicit immunological
memory. The goal of carbohydrate-based vaccines is the
creation of a strong, specific and long-lasting immune response
that is able to destroy the pathogen quickly with the help of B-
and T-cells. Polysaccharide vaccines, however, consist exclu-
sively of T-independent antigens, and thus cannot efficiently
stimulate neonatal B cells.
In 1923, Heidelberger discovered that the immunodominant
type-specific substance of Streptococcus pneumoniae is a
polysaccharide7 before it was realized that the conjugation of
monosaccharides to proteins enables the generation of
saccharide-specific antibodies in vivo.8,9 CPS from S. pneumo-
niae were found to induce specific protection against the
pathogen and this represented the advent of polysaccharide
vaccines.10 Chemical attachment of type III pneumococci CPS
to proteins from horse serum in 1931 allowed for successful
vaccination of rabbits with these conjugates. Thus, the proof-of-
principle for glycoconjugate vaccine efficacy against pathogenic
bacteria was established 90 years ago.11
1.2.1. Polysaccharide Vaccines. In the 1970s, poly-
saccharide vaccines were licensed against Neisseria meningitidis
and S. pneumoniae. The first pneumococcal polysaccharide
vaccine contained CPS from 14 different serotypes followed by a
23-valent formulation, along with further polysaccharide
vaccines against pathogenic bacteria.12 Despite the remarkable
success of polysaccharide vaccines in preventing invasive
disease, polysaccharides were not effective in protecting infants
with their immature immune systems from pathogens.13 While
there is no clear-cut age at which the immune system starts to
produce antibodies against T-independent antigens, it is
believed that polysaccharide vaccines are not effective in infants
under the age of 24 months.14 The Haemophilus inf luenzae type
b (Hib) polysaccharide vaccine introduced in 1985 was
withdrawn from the market in 1988 and replaced by CPS-
protein conjugate vaccine formulations (see section 1.2.2).15
The pneumococcal polysaccharide vaccine PPV-23 (Pneumo-
vax23, Merck) is recommended for children older than two
years.16 Polysaccharide vaccines against N. meningitidis
(Menomune, Sanofi Pasteur) and Salmonella enterica sv. Typhi
(Typhim Vi, Sanofi Pasteur) are currently marketed but not
recommended for infants.
1.2.2. Carbohydrate Conjugate Vaccines. To overcome
the immunogenicity problems with polysaccharides in young
infants and the elderly, the two main groups at risk, and to
improve the immunogenicity of carbohydrate epitopes by
inducing a T-cell mediated immune response, the classical
approach of conjugating polysaccharides to proteins was used.
Tetanus toxoid (TT), diphtheria toxoid (DT), or cross-reacting
material (CRM 197) a detoxified variant of DT have been used
as carrier proteins.17 Upon processing by dendritic cells, the
glycan epitopes are presented to T-helper cells by the major
histocompatibility complex (MHC). Both cellular and cytokine-
mediated signals then induce maturation and proliferation of the
glycan-specific B cells and a memory response. High-affinity
antibodies toward CPS and immunological memory are induced
even in children under the age of two.18,19 Glycoconjugate
vaccines have helped to significantly decrease the incidence of
invasive diseases caused by pathogenic bacteria. Today,
glycoconjugate vaccines constitute a multibillion dollar market
and are included in immunization programs recommended by
health authorities worldwide.20
Carbohydrate conjugate vaccines have almost completely
replaced polysaccharide vaccines. Conjugate vaccines against
Hib are a part of pentavalent vaccine combinations.15 Pneumo-
coccal conjugate vaccines have been developed to cover an
increasing number of serotypes, and current formulations are
10- (Synflorix, GSK) and 13-valent (Prevnar13, Pfizer).21
Conjugate vaccines against pneumonia have been an immense
medical and commercial success. Novel glycoconjugate vaccines
against a variety of pathogens are in development.22,23
Most marketed glycoconjugate vaccines contain saccharides
isolated from cultured bacteria. Bacteria are killed by heat or
chemical treatment prior to CPS precipitation. Purification of
CPS by ultracentrifugation, gel permeation, enzyme treatment
and ultrafiltration results in polysaccharides with less than 3%
nucleic acid and protein contaminations.24 Purified CPS are
depolymerized by microfluidization or enzymatic degradation
and the size distribution of the fragments is determined by size
exclusion chromatography and many other techniques.25
CPS fragments are chemically activated for conjugation to the
carrier protein.26 Single point attachment utilizes one reactive
functional group per CPS fragment, typically the anomeric
carbon of the reducing end monosaccharide, to connect it via
reductive amination to a lysine side chain of the carrier.27 Single
point attachment methods yield “neoglycoconjugates” that
stand in contrast to methods that introduce multiple reactive
groups per CPS fragment, leading to cross-linked carrier-glycan
lattices. For example, multipoint attachment can be performed
via carbodiimide coupling of uronic acids and cyanogen bromide
activation of vicinal hydroxyl groups.28−30 Alternatively, period-
ate oxidation of saccharides generates aldehyde groups that
engage in reductive amination.31 Conjugation via thioether
formation between thiolated polysaccharide fragments and
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haloacylated carrier proteins ensures chemoselective cou-
plings.32,33 The choice of the conjugation method has to be
matched to the functional groups available on the carrier
protein. Toxins like DT and TT are usually inactivated by
treatment with amine-reactive reagents like formaldehyde.
Inactivation reduces the availability of reactive lysine residues,
and therefore toxoid carriers are preactivated and spacer
molecules are incorporated during conjugation.34 It must be
assessed whether any reactive groups remain in the conjugate.
The saccharide-to-protein ratio must be reproducible for
different vaccine lots and the amount of free, unconjugated
glycan chains must be determined.35
Adjuvants are immunostimulatory components that are
added to the vaccine to improve the immune response. For
human use, mainly aluminum salts such as aluminum phosphate
or aluminum hydroxide are added.36 The vaccine formulation
contains the glycoconjugate that is adsorbed onto the aluminum
salt. The formulated product is either stored as a lyophilized
powder or as a suspension. The vaccine has to be kept cold at all
times in order to avoid denaturation of the protein and
potentially harmful side effects. The cost of cold chain
maintenance can represent as much as half of the overall cost.
All current glycoconjugate vaccines have to be delivered by
injection, which complicates administration in developing
countries.
1.2.3. Semisynthetic Carbohydrate Conjugate Vac-
cines. Despite the immense medical and commercial success of
conjugate vaccines based on isolated polysaccharides, their
development was challenging and took decades to accomplish.
The procurement of glycans for the production of conjugate
vaccines reaches its limits in cases where the pathogen cannot be
cultured or the isolation of the glycan is too difficult. Not every
bacterial strain can be cultured easily. Even if a strain can be
cultured, the production of the correct CPS in sufficient
quantities requires careful process optimization.37,38 Some labile
polysaccharides may decompose during isolation.39,40 Very
stable polysaccharides such as the CPS on Salmonella typhiimay
be difficult to depolymerize.41 Isolated polysaccharide prepara-
tions inevitably contain small amounts of impurities, such as the
pneumococcal C-polysaccharide that are not found in synthetic
glycans.
Methods to synthesize the glycan epitope have been explored
since the late 1980s.42−47 A semisynthetic glycoconjugate
vaccine (QuimiHib) was developed in Cuba and is marketed
in several South American countries.48 In this case, not a single
glycotope was used but rather a mixture of oligosaccharides of
different length that were prepared by polymerization of a
synthetic building block. Conjugation of the synthetic glycans to
TT-carrier protein yielded a semisynthetic glycoconjugate
vaccine that has proven highly effective since its introduction
over a decade ago. To date, no other semisynthetic vaccine has
been marketed, owing to a bias in the vaccine industry against
the adoption of new technologies.
1.2.4. Fully Synthetic Carbohydrate Conjugate Vac-
cines. Conceptually, molecularly completely defined, fully
synthetic carbohydrate-conjugate vaccines are desirable. Syn-
thetic oligosaccharide antigens will replace isolated polysac-
charides, a synthetic carrier such as a glycolipid or synthetic
peptide may substitute an expressed protein and ideally
synthetic constructs would no longer require an adjuvant
(Figure 1). Such fully synthetic vaccines would be pharmaceut-
icals rather than biologicals. While the creation of such vaccines
is conceivable, none of these vaccine candidates has yet gone
past the exploratory stage into clinical trials.49
1.3. Synthetic Carbohydrate Vaccine Development Process
A medicinal chemistry approach toward glycoconjugate vaccine
development requires a fundamental understanding of how the
human immune system recognizes cell-surface glycans and how
this recognition process results in a B-cell and T-cell response
that in turn induces the killing of bacterial pathogens. A
multidisciplinary effort of chemists, immunologists, and
eventually structural biologists needs to focus on the
identification of a specific, protective oligosaccharide as part of
the synthetic carbohydrate vaccine development process
(Figure 2).
1.3.1. Selecting the Target Disease. Any pathogen that
carries unique glycans on its surface is in principle a target for the
development of glycoconjugate vaccines or treatment with
monoclonal antibodies. Most Gram-negative bacteria as well as
many protozoan parasites carry signature glycoconjugates on
their cell surface. In selecting a vaccine target, the medical need
Figure 1. Glycoconjugate vaccine concept; (a) The traditional
approach and (b) the semisynthetic or fully synthetic glycoconjugate
vaccine approach.
Figure 2. Overall process of synthetic carbohydrate vaccine develop-
ment.
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and insights concerning the cell-surface glycans are important.
Ideally, the structures of the pathogen cell surface glycans in
question are known and the chosen glycan is unique and, to
avoid autoimmunity, differs from any human cell-surface
glycans.
1.3.1.1. Streptococcus pneumoniae. S. pneumoniae one of
the most important human pathogens, is endemic globally and
the most common cause of acute otitis media, sinusitis,
pneumonia, and bacterial meningitis. In developing countries,
pneumonia is a serious pediatric disease, and it is estimated that
more than a million children below the age of five die each year
from pneumococcal pneumonia.50 Initially, unconjugated
polysaccharides were used for vaccination (Pneumovax 23
(PPV-23) from Merck), but these preparations suffered from
poor immunogenicity. S. pneumoniae carbohydrate conjugate
vaccines have become blockbusters. The 13-valent glycoconju-
gate vaccine Prevnar-13 from Pfizer dominates the market over
ten-valent Synflorix from GSK. These glycoconjugate vaccines
have dramatically reduced the number of deaths due to S.
pneumoniae infections. The existence of more than 90 different
serotypes renders development of a universal vaccine challeng-
ing.51
Currently available pneumococcal vaccines were based on
epidemiological and prevalence data for North America and
Europe. Many of the serotypes that are prevalent in developing
and emerging nations are missing in these vaccines. Therefore,
some national health agencies are reluctant to introduce the
vaccine into their national vaccination programs. Moreover, the
immune response induced against each serotype varies greatly.
This can be attributed to differences in chain length, epitope
number, and distribution. Since these vaccines are based on
isolated polysaccharides, reproducibly controlling glycan chain
length is very difficult.
1.3.1.2. Haemophilus inf luenzae type b (Hib). Hib
infections are widespread throughout the world and may
develop under various scenarios with meningitis being the
most frequent outcome. Worldwide, Hib infections account for
three million cases of severe illness and 400 000 deaths annually,
with a peak of incidence among infants of age 4 to 18 months.52
Following colonization of the pharynx, the Gram-negative
bacterium may enter the bloodstream and subsequently spread
to reach various target organs resulting in different clinical forms
of Hib disease including meningitis, pneumonia, and arthritis.
Hib meningitis is often fatal (5−40% of cases depending on the
country) andmay lead to neurological sequelae such as deafness,
motor deficit, or mental retardation. Medical management relies
on intensive care and appropriate antibiotic therapy.
The Hib vaccine is usually administered along with the other
vaccines included in the childhood vaccination schedule and has
resulted in a rapid decline in the number of cases in
industrialized countries but is not used everywhere.53−55 A
semisynthetic glycoconjugate vaccine (QuimiHib) was devel-
oped in Cuba and is marketed in several South American
countries.48 Some of the currently marketed Hib vaccines face
stability issues as the Hib polysaccharide is not stable for long
periods of time when formulated with alum. Therefore, the
lyophilized vaccine has to be solubilized by the physician just
prior to injection. Vaccine formulations that circumvent that
stability issue have been commercially more successful in recent
years.
1.3.1.3. Neisseria meningitidis. N. meningitidis is a leading
cause of bacterial meningitis and the only Gram-negative
encapsulated bacterium responsible for large epidemics.56
Bacterial meningitis accounts for 1.2 million cases of the disease
worldwide annually, affecting mostly infants, children, and
young adults who do not have specific protective antibodies.57
Out of the 13 serotypes, the most prevalent are A, B, C, W135,
and Y. Two types of polysaccharides, CPS and lipopolysacchar-
ide (LPS), are the major virulence factors in N. meningitidis
infections. There are currently several quadrivalent vaccines
available to prevent meningococcal disease, all by targeting
serogroups A, C, W-135, and Y. In addition to conjugate
vaccines, a polysaccharide vaccine is being marketed.58−60 A
protein-based vaccine for serotype B gained approval in 2013.61
1.3.1.4. Clostridium difficile. The Gram-positive, spore-
forming bacterium C. dif f icile is the most common cause of
nosocomial diarrhea worldwide.62 The disruption of intestinal
flora by antibiotic administration allows for colonization by and/
or overgrowth of drug-resistant, toxin-producing C. dif f icile
spores. The disease is mostly associated with hospital and long-
term care facilities. Risk factors for C. dif f icile infections (CDIs)
include broad-spectrum antibiotic use, hospitalization, and
advanced age. Over 450 000 CDI cases cause about 30 000
deaths and over $4.8 billion medical costs annually in the U.S.
alone. In recent years, infection and death rates have been
increasing drastically. In addition to the main risk group, the
elderly, children, young adults and pregnant women are now
infected, thereby increasing the social and economic burden.63
The emergence of new C. dif f icile strains, such as ribotype 027
that has quickly spread with increased virulence, toxin
production, and antibiotic resistance is partially responsible for
this development.64 Vaccination as an alternative to antibiotic
treatment is highly desirable. Toxin-neutralizing immunization
can protect against lethal challenge with C. dif f icile in hamsters,
but toxin-based vaccines cannot inhibit bacterial colonization,
which precedes toxin production.65 Recurrent CDIs are serious
clinical problems affecting about 20% of patients after cessation
of therapy, either due to recolonialization by the same or
reinfection with a different C. dif f icile strain.66 Preventing
colonialization by vaccination against surface antigens may limit
recurrence more effectively than toxin-neutralizing approaches.
Several cell-surface glycans of C. dif f icile have been charac-
terized.67,68
1.3.1.5. Klebsiella pneumoniae. K. pneumoniae (Kp) is the
leading cause of nosocomial respiratory and urinary tract
infections, as well as bacteremia, primarily among newborns and
immunocompromised patients.69 Carbapenem-resistant Kp
(CR-Kp) are now commonly encountered in hospitals world-
wide. Outbreaks occur with increasing frequency;70−72 strains
spread quickly73 and cause high morbidity and mortality. Most
clinical CR-Kp isolates contain a dominant strain, sequence type
258 (ST258), that expresses Kp carbapenemase. Efficacious
vaccination of risk groups is direly needed as treatment options
for CR-Kp are diminishing. Currently, there are no vaccines
against Kp available.
1.3.1.6. Group A Streptococcus. Group A Streptococcus
(GAS) infections are a global concern as they cause a broad
spectrum of diseases ranging from asymptomatic colonization
and uncomplicated skin infections to life-threatening invasive
illnesses including sepsis and toxic shock syndrome.74
Pharyngitis may lead to delayed sequelae such as rheumatic
fever. While GAS has been on the WHO priority prevention list
for decades, currently, no vaccine to prevent GAS infections
exists.
1.3.1.7. Shigella. Gram-negative, facultative anaerobic
Shigella bacteria cause bacillary dysentery (shigellosis) for
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which there is no broadly available vaccine. It is estimated that
every year 800 000 people, mainly children under five years of
age in developing countries, die from diarrheal diseases.75
Shigellae and enterotoxigenic Escherichia coli (ETEC) are also
major causes of morbidity and mortality among older children,
adolescents, and adults. Pathogenic Shigellae are highly
infectious and are transmitted through person-to-person contact
and contaminated food. An effective, multivalent vaccine against
shigellosis that covers multiple species and serotypes is a global
priority. Four major Shigella species are distinguished on the
basis of the O-specific polysaccharide (O-SP) structure of their
cell surface lipopolysaccharide. S. f lexneri, with at least 15
serotypes and subserotypes, and S. sonnei, with only one
serotype, are the species responsible for the vast majority of
cases worldwide.76 Most Shigella vaccine candidates intend to
induce an antibody response against the LPS that is both a
virulence factor and a major surface protective antigen.77
1.3.1.8. Salmonella typhii. Typhoid fever, caused by the
Gram-negative bacterium Salmonella enterica serovar typhi, is
closely associated with poor food hygiene and inadequate
sanitation. After ingestion of contaminated food and water,
Salmonellae penetrate the gut epithelium to spread to visceral
tissues, including liver and spleen. Patients experience fatigue,
headache, abdominal pain, fever, and constipation or diarrhea.
Severe forms may entail cerebral dysfunction, delirium, and
shock. S. typhi causes typhoid in humans.78
About 16 million cases of typhoid fever result in
approximately 600 000 deaths globally every year. The incidence
of typhoid fever peaks between the ages of 5 and 12 years in
endemic areas. In recent years S. typhi has gradually acquired
resistance to oral antibiotics. Nonavailability of drugs and
developing drug resistance render an efficacious and affordable
vaccine highly desirable.79
1.3.2. Selecting the Cell-Surface Glycan Target.Once a
pathogen has been identified as a potential vaccine target based
on a specific medical need, information concerning the
composition of the cell-surface glycans present on the pathogen
are essential. Many pathogenic bacteria, fungi, and protozoan
parasites cover themselves with a layer of CPS, LPS, and related
structures (Figure 3).80 Microorganisms use these capsules to
prevent desiccation and escape from components of the innate
immune system by shielding other cell surface antigens.81
Figure 3. Schematic view of (a) capsular polysaccharide (CPS), (b) lipopolysaccharide (LPS), and (c) glycerophosphatidylinositol (GPI) anchors. n =
number of repeating units.
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Capsules are major virulence factors since they prevent
complement activation and opsonization.82 Most CPS are
biosynthesized in a modular manner from oligosaccharide
precursors, and hence usually consist of repeating units (RUs).83
Knowledge concerning the structure of CPS, O-antigens, or
glycolipids is gained by isolation of the cell-surface glycans from
cultured bacteria followed by chemical degradation and detailed
structural elucidation based on physical methods such as NMR
spectroscopy. This provides insights concerning the size and the
composition of the RU. The structural diversity of CPS of
pathogenic bacteria is enormous.84 In S. pneumoniae, more than
90 different CPS RU structures are distinguished and serotypes
assigned.85 RU length ranges from mono- to octasaccharides86
and the backbone in some cases comprises phosphodiester
linkages, as is the case for H. inf luenzae type b. Polysaccharides
may be linear or branched and contain common or rare sugars.
While human cell surface glycans are composed of just nine
different monosaccharides, the number of building blocks that
make up the bacterial glycome is in the hundreds.84
Monosaccharides may be present in pyranose or furanose
forms or as open chain polyalcohols. Covalent modification with
groups such as acetate, phosphate, pyruvate, or glycerate further
increases structural variability. Rare monosaccharides, unusual
linkages, and modifications likely contribute to the nonself
recognition of bacterial CPS by the human immune system.
The pathogenicity and virulence of Gram-negative bacteria
are often associated with the LPS coat.85 LPS, a highly complex
glycolipid, is the major component of the outer membrane of
Gram-negative bacteria. LPS is comprised of the lipid A moiety,
the core oligosaccharide, and the O-specific polysaccharide
(Figure 3b). The core oligosaccharide, connecting lipid A with
the outer O-antigen, is present in every natural LPS structure.
The O-antigen in turn may be missing in many pathogenic
bacteria such as N. meningitidis and H. inf luenzae. Structurally,
the core region of LPS can be further subdivided into inner core
and outer core. The main structural motifs of the inner core are
highly conserved throughout the Gram-negative bacteria while
the sugars of the outer core vary greatly between strains.87 3-
Deoxy-α-D-manno-oct-2-ulosonic acid (Kdo) and L -glycero-D-
manno-heptose (Hep) are ubiquitously present in every LPS
structure (Figure 4). Most Gram-negative bacteria share the
trisaccharide L,D-Hep-(1 → 3)-L,D-Hep-(1 → 5)-Kdo as a
common conserved inner core structure. This core can be
decorated with other glycans, phosphates, or occasionally acetyl
groups.
As a potent virulence factor, LPS also serves as a surface
pathogen-associated antigen for recognition by the host immune
system.88 Therefore, LPS has attracted much interest for the
development of vaccine candidates.
Protozoan cell membranes are rich in glycerophosphatidyli-
nositol (GPI) anchors that are often linked to cell surface
proteins (Figure 3c). GPI anchors can activate components of
the innate immune system, such as Toll-like receptors (TLR).89
Protozoan GPIs have been shown to induce the generation of
specific antibodies and may thus be the antigens of choice for
vaccination against these parasites.90 A fully synthetic GPI
provided efficient protection against Plasmodium infections
when conjugated to a carrier protein,91 while immunization with
GPI-anchored proteins derived from themulticellular trematode
Schistosoma mansonii protected mice from this parasite.92
1.3.3. Synthetic Oligosaccharides as Basis for Glyco-
tope Identification.When a disease target for vaccination has
been identified and the composition of one or more unique
glycans of the pathogen cell surface are known, a carbohydrate
conjugate vaccine program commences with medicinal chem-
istry work focused on identifying the minimally protective
epitope. The length of the antigen has to be determined, the
frameshift of the RUhas to be worked out, and the importance of
unusual sugars that are not found in the human repertoire, as
well as the importance of covalent modifications, have to be
determined.
Ultimately, designing a carbohydrate from first-principles
based simply on the knowledge concerning the composition of
the cell surface glycan would be highly desirable. Currently,
however, our understanding of what makes a glycan
immunogenic and antigenic is too rudimentary to take a rational
design approach. Therefore, series of synthetic glycans related to
the cell-surface glycan target are prepared to serve as tools for the
identification of a lead antigen. Since the isolation of specific
glycans is difficult and cannot rely on amplification procedures,
chemical and enzymatic syntheses, or combinations thereof,
have served to procure these molecules.
1.3.3.1. Traditional Synthesis of Oligosaccharide Antigens.
Chemical solution-phase syntheses have helped to define
minimal glycotopes for use in semisynthetic glycoconjugate
vaccines since the 1980s.28−30 The fundamental challenges of
glycan synthesis are protecting group manipulations and
stereochemical control over glycosidic bond formation. The
selective exposure of one hydroxyl group allows for
regioselective addition of another (mono)saccharide unit.93
The choice of protecting groups and the order of protecting
group installation are essential for a synthesis route to be
successful. A major challenge in glycan synthesis is the
stereoselective formation of glycosidic bonds. A variety of
methods are available to stereoselectively generate glycosidic
linkages. The yield and the stereochemical outcome of these
reactions depend on the steric and electronic nature of the
glycosylating agent (the glycosyl donor), as well as the nature of
the nucleophile and the reaction conditions chosen.93
1.3.3.2. Automated Glycan Assembly of Oligosaccharide
Antigens. The chemical synthesis of defined carbohydrates
remained challenging and time-consuming at a time when
automated peptide94 and oligonucleotide95 syntheses had
become routine. The concept of automated glycan assembly
(AGA) was introduced in 200196 and systematically improved
over the following two decades. Today, synthetic glycans as long
as 100-mers97 have been assembled by AGA.98 The streamlined
AGA process can rely now on a commercial Glyconeer 2.1
Figure 4. Conserved inner core oligosaccharides of LPS from Y. pestis,
H. inf luenzae, and Proteus. (A) 3-Deoxy-α-D-manno-oct-2-ulosonic acid
(Kdo); (B, C, D, and E) L-glycero-D-manno-heptose (Hep); (F) 4-
amino-4-deoxy-β-L-arabinose (Ara4N).
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automated oligosaccharide synthesizer (Figure 5) and commer-
cially available monosaccharide building blocks to rapidly
assemble conjugation-ready oligosaccharides.99 Rapid access
to defined carbohydrate antigens via AGA has drastically
accelerated the medicinal chemistry approach by preparing
collections of oligosaccharides quickly.
1.3.4. Glycan Microarray Analysis of Sera to Identify
Antigen Hits. The classical approach to assess the antigenicity
of oligosaccharides involves immunization trials with the
glycoconjugates of interest. The affinities of antisera from
immunized animals to conjugated oligosaccharides and native
CPS are determined.100 Antisera or monoclonal antibodies are
tested for their ability to bind pathogens and promote
phagocytosis.101,102 More recent approaches of epitope
mapping employ screening of antibodies from infected or
immunized individuals for binding to synthetic oligosacchar-
ides.103 Uncovering a potential antigenic polysaccharide epitope
by means other than immunization can help to reduce the
number of required animal trials.
Carbohydrate microarrays that carry hundreds of different
sugars bound covalently in small spots on surfaces are now a
standard tool for glycobiologists (Figure 6).103 Theminiaturized
array methodology is well suited for serological investigations as
only tiny amounts of both glycan and blood serum are required
and many binding events can be screened in parallel. Access to
defined bacterial glycans has been the bottleneck for the use of
glycan arrays. With accelerated methods to assemble bacterial
oligosaccharides, screening of patient samples such as blood and
stool with the help of glycan microarrays has been greatly
facilitated.
Screening clinical blood or stool samples using glycan arrays
provides insights into the antigenicity of cell-surface glycan
epitopes by detecting the presence of antibodies (in samples
from patients compared to healthy controls) that recognize
synthetic glycans resembling cell-surface RUs and related
oligosaccharides. When a bacterium colonizes the lungs and is
found in the blood, as is the case for S. pneumoniae, IgM and IgG
antibody levels are determined. For gut bacteria such as C.
dif f icile, the interaction with IgA antibodies is assessed.104 If a
correlation between the presence of antibodies and disease
outcome can be established, such that patients with antibodies
show milder forms of the disease, this indicates a good lead for
the development of a carbohydrate based vaccine. Microarrays
of synthetic GPI glycans helped to demonstrate that adults in
endemic areas are protected from severe malaria by antiglycan
antibodies.105 Similarly, the GPI anchor of T. gondii was
identified as a diagnostic marker for toxoplasmosis.106
1.3.5. Determination of the Minimal Glycotope and
Selection of Oligosaccharides for Immunological Eval-
uation. Screening of sera from patients as well as reference sera
provides insights into the potential glycotope. To obtain a
molecular level picture, a series of oligosaccharides related to the
glycans bound by the serum antibodies is prepared. In some
cases, protective monoclonal antibodies have been identified
against a disease and the synthetic oligosaccharides can serve to
provide insights into the nature of a protective glycotope. The
oligosaccharides differ in length, frameshift, terminal mono-
saccharide, and covalent modifications (thus can also differ in
net charge). When potentially labile functional groups are found
within the glycotope, stable analogues may be tested as well.
The synthetic oligosaccharides are equipped with a unique
terminal functional group such as an amine or a thiol that
facilitate covalent attachment to the surface of arrays and to
carriers for immunological studies. Binding of monoclonal
antibodies to different oligosaccharides is tested on glycan
arrays. The interactions are tested for specificity using native
CPS or LPS to block the interaction. This process identifies one
or more candidates for further immunological evaluation.103
Figure 5. First commercially available automated oligosaccharide
synthesizer.
Figure 6. Glycan microarray screening of protein-carbohydrate
interactions. Based on the experimental design, different glycans are
printed onto standard microarray slides. Special targeted arrays are
designed to contain glycan subsets for high throughput screening, such
as serum analysis.
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1.3.6. Preparation of Glycoconjugates. Since most
glycans cannot induce a T-cell-mediated immune response,
the carbohydrate antigen has to be connected to a carrier.
Currently marketed vaccines contain as carrier protein
diphtheria toxoid (DT), tetanus toxoid (TT) or a detoxified
version thereof, such as CRM197. These carrier proteins are
isolated following either homologous or heterologous expres-
sion in bioreactors, using well-characterized bacterial strains.107
The proteins are purified by chromatography, sterile filtered and
analyzed for homogeneity and structure.108,109 A host of
methods for the preparation of carbohydrate−protein con-
jugates have been developed and proper conjugation chemistry
is key to efficient glycoconjugate production.110 A linker must be
selected that induces minimal undesired immunogenic
responses. For example, thiol modified oligosaccharides can be
readily conjugated to maleimide-containing CRM197 in
phosphate buffer at room temperature to afford glycoconjugates.
Alternatively, synthetic oligosaccharides containing a terminal
amine are converted into the p-nitrophenyladipate ester111
derivative and covalently coupled to, for example, lysine side
chains in CRM197.
Ideally, the number of oligosaccharides conjugated to each
CRM197 protein is calculated from the mass shift measured
using MALDI-TOF MS. Typically, between four and ten of the
40 lysine residues available in CRM197 are coupled to an
oligosaccharide.112 Further characterization of the glycoconju-
gates is performed using SDS-polyacrylamide gel electro-
phoresis (SDS-PAGE) confirming an increase in molecular
weight. Glycan content determination to confirm the loading
from MALDI is based on high performance anion exchange
chromatography with pulsed amperometric detection (HPAEC-
PAD) after alkaline hydrolysis.113−115
Many new carrier strategies focus on multivalent hapten
presentation. Encouraging results in vaccination experiments
have been obtained with oligosaccharide-bound virosomes,
liposomes and gold nanoparticles (GNP).116 The fate of fully
synthetic carriers, such as GNP, inside an organism is often
unclear. Thus, both in vivo toxicity and clearance pathways have
to be accurately assessed for these materials.
1.3.7. Glycoconjugate Formulation. Covalent attach-
ment of carbohydrate antigens to carrier proteins produces
neoglycoconjugates that, unlike native carbohydrates, induce a
T cell-dependent immune response. The addition of immunos-
timulatory substances, adjuvants, helps to boost the immune
system to provide a strong response. Glycoconjugates are often
formulated either with Alum (Alhydrogel; aluminum hydrox-
ide) or Freund’s Adjuvant (FA). Alum is an adjuvant that is
approved for use in human vaccines. Freund’s adjuvant is an
effective adjuvant in mice that has been successfully employed to
raise antibodies to a synthetic oligosaccharide antigen but is not
allowed to be used in humans due to its toxicity.117 Finally, after
formulating the conjugate with an adjuvant, the stability of the
glycoconjugate may be assessed.,15,107118
1.3.8. In Vivo Immunogenicity Tests. To test the
immunogenicity of glycoconjugates, either mice or rabbits are
used. Mice are convenient as they are inexpensive and easy to
keep. The immune system of rabbits is however closer to that of
humans and the immunological results that are obtained are a
better predictor for a human response. Groups of mice or rabbits
are immunized subcutaneously with doses of glycoconjugate
formulated either with FA or Alum. An immunization schedule
follows a prime-boost regime whereby the formulated
glycoconjugate is subcutaneously injected up to three times at
14 day intervals.
The antihapten antibody titers are monitored using glycan
array analysis. The immunogenicity of synthetic antigens is often
strongly dependent on the adjuvant formulation. Conjugates
formulated in FA often induce higher antibody titers in mice
when compared to Alum formulated conjugates. Microarrays
also include CRM197 to assess antibody responses to the carrier
protein and the generic spacer moiety. IgG, IgM, and IgA isotype
antibodies to the oligosaccharide antigen are detected to assess
whether immunoglobulin class switching is induced. Freund’s
adjuvant often elicits higher antibody levels than Alum.119
Nonadjuvanted glycoconjugates may be immunogenic as well,
but induce a weaker and shorter-lived antibody response. At a
given time point, IgG levels are expressed as mean fluorescence
intensity (MFI) and compared between different adjuvanted
groups.
Glycan microarrays assist in epitope mapping and identify its
minimum size. Antibodies raised using a particular glycoconju-
gate often not only recognize the antigen used for immunization
but also related shorter oligosaccharides. The epitope
recognition pattern in animals immunized with glycoconjugates
formulated with different adjuvants often differ.119
To gain further insights into the nature of the humoral
immune response to the epitopes, and the differences observed
in mice immunized with different adjuvants, binding of serum
antibodies to epitopes can be analyzed by surface plasmon
resonance (SPR). Antibodies in the sera may show increasing
binding and stability values over time, indicating affinity
maturation to epitopes during the course of the immune
response.
In many cases, especially for Hib vaccines, Zika rabbits are the
animal model of choice. As for mice, groups of rabbits are
immunized in a prime-boost regime with glycoconjugate
formulated with adjuvant. The analysis of the immune response
in rabbits follows the protocols developed for mice.120
1.3.9. Monoclonal Antibodies Against Synthetic
Epitopes. Understanding how complex carbohydrates interact
with antibodies is a first step toward establishing rules for
carbohydrate antigen design. The detailed analysis of a
monoclonal antibody was performed for a tetrasaccharide
component of the Bacillus collagen-like protein of anthracis
(BclA) glycoprotein, found on the surface of the spores of
Bacillus anthracis, the agent that causes the acute zoonotic
disease, anthrax. A tetrasaccharide-conjugate elicited IgG
antibodies that bind specifically to native B. anthracis endo-
spores.121 These antibodies were the basis for a commercial
diagnostic anthrax test. Crucial antibody-binding positions on
the sugar antigen were identified using a combination of
synthetic glycan microarray screening, surface plasmon
resonance (SPR), and saturation transfer difference (STD)
NMR analysis.121
To uncover the structural elements of the carbohydrate that
influence this selectivity, microarray screening was performed
using a family of synthetic oligosaccharides related to the
original BclA tetrasaccharide. These synthetic glycans were
screened for their ability to bind the antidisaccharide and
antitetrasaccharide mAbs. Glycan array screening revealed
anthrose is the minimal unit required for binding antidisacchar-
ide mAbs.
Quantification of the carbohydrate-antibody binding inter-
actions was performed by SPR and compared to the qualitative
glycan array screening results. SPR analysis also reveals
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interaction kinetics. STD NMR is particularly suited for
characterizing binding differences within ligands to discriminate
tightly bound domains from weakly bound domains without
having to assign the resonances of the macromolecular receptor.
However, slow kinetics results in very limited transfer of ligands
from the antibody-bound state to the free state, and greatly affect
the signal-to-noise ratio of STDNMR experiments. Strong STD
effects indicate tight-binding sites. These interactions can be
located throughout the entire glycan, as was the case for B.
anthracis tetrasaccharide, with a cluster of tight-binding sites
found within the anthrose-(β1−3)-rhamnose substructure
(Figure 7). A combination of microarray profiling, SPR, and
STD NMR allows for precise mapping of the molecular
elements of glycan-antibody binding. The approach is a general
tool that may ultimately help to elucidate the general principles
of carbohydrate-antibody interactions, enabling guided struc-
ture-based design of a broad spectrum of carbohydrate-based
antigens and therapeutics.121
1.3.10. Opsonophagocytic Killing As a Test for
Bactericidal Activity. Protective antibodies often function
by opsonization and promote complement-mediated lysis of
target pathogens.53 Therefore, typically sera from immunized
mice or rabbits are tested for their opsonophagocytic potential in
a standardized opsonophagocytosis assay (OPA).122 Human
promyelocytic leukemia cells (HL-60) are differentiated into
neutrophil-like cells before bacterial cells are incubated with test
sera from naiv̈e or immunized animals and then added to
differentiated HL-60 cells in the presence of complement. After
1 h, the remaining viable bacterial cells are quantified by plating
and subsequent counting of colonies (CFU-assay). Serum from
immunized animals is expected to mediate dose-dependent
killing of bacteria demonstrating that the conjugate vaccine
elicits opsonophagocytic antibodies. Antibacterial serum anti-
body titers as well as opsonophagocytic activity are typically
strongly dependent on the adjuvant. FA typically elicits higher
antibody titers with higher killing-activity in the OPA assay
compared to aluminum phosphate adjuvanted glycoconjugates.
1.3.11. Animal Challenge Experiments to Compare
Vaccinated and Control Groups. After establishing that a
glycoconjugate is immunogenic, its immunoprotective proper-
ties against a bacterium of interest are evaluated in an
appropriate animal model. The glycoconjugate is typically
formulated with Alum as an adjuvant allowed for use in humans
or is used unadjuvanted. Animals are typically immunized three
times in two week intervals with 2−5 μg of glycoconjugate per
immunization and antibody titers are measured. The naiv̈e mice
and those immunized with glycoconjugate are then infected with
the bacterium of interest and clinical signs of disease are
monitored. As a direct indicator of antibacterial defense in naiv̈e
and immunized mice, bacterial burdens at a certain time point
are quantified to assess the protective effects of immunization on
bacterial growth. Ideally, immunization with glycoconjugate
reduces bacterial loads when compared to PBS-treated animals
or those immunized with the glycoconjugate without adjuvant.
Moreover, immunization should almost completely prevent
bacteremia that is observed in vaccine-naiv̈e control animals.
Induction of long-lived immunity is an important feature of
successful vaccination. When mice are used as a model system,
resting the animal for 90 days following the last booster shot
before one additional dose is given tests the long-term response.
Prior to the final injection, the antibody levels have typically
dropped to very low levels but rapidly rise upon a boost. Good
long-term effects of glycoconjugate immunization and a
boostable immune response are important positive indicators
for the preclinical and clinical development of carbohydrate-
conjugate vaccine candidates.
2. CASE STUDIES OF SEMI-SYNTHETIC
GLYCOCONJUGATE VACCINE DEVELOPMENT
The conceptual path to identify a semisynthetic vaccine
candidate for further preclinical and clinical development
(section 1.3) has been followed for different pathogens and
many different serotypes. In this section, specific lessons learned
during the development of vaccine candidates will be discussed.
2.1. Synthetic Glycotope
Currently marketed vaccines based on isolated polysaccharides
contain a myriad of glycotopes that are presented to the immune
system. The initial focus of the development of semi- or fully
synthetic glycoconjugate vaccines is the medicinal chemistry
effort aimed at identifying a single protective epitope.
Identification of such a minimal epitope provides the basis for
further development but also constitutes the composition of
matter intellectual property to protect the vaccine product.
Based on insights concerning the RU of a bacterial CPS or a LPS
structure, a host of questions must be answered experimentally:
(i)What is theminimally required length of the glycotope, is one
RU enough or are several needed? (ii) What frameshift is best to
use, or in other words, which should be the terminal glycan? (iii)
Are covalent modifications of the glycan backbone important?
(iv) Are there any labile groups in the antigen that might be
altered during the conjugation process to the carrier? Typically,
multiple rounds of chemical synthesis of a host of
oligosaccharides (see section 1.3.3) and subsequent immuno-
logical evaluation (see sections 1.3.4−1.3.8) are required.
Figure 7. Epitope mapping of a synthetic tetrasaccharide resembling
glycans on the surface of Bacillus anthracis and a monoclonal antibody
raise against this tetrasaccharide epitope by STD NMR spectroscopy.
STD effects are shown for individual protons of the tetrasaccharide and
strong (>10%), medium (5−10%), and weak (<5%) STD effects are
indicated by red, orange, and yellow spheres of decreasing size.
Reprinted with permission from ref 121. Copyright 2010 American
Chemical Society.
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2.1.1. Glycotope Length. Since pathogens such as bacteria
are surrounded by polysaccharides often containing hundreds of
monosaccharides, the fundamental question for the develop-
ment of synthetic oligosaccharide-based vaccines concerns the
size of the glycan epitope required to induce a protective
immune response in a living organism. At the outset of the work
on synthetic carbohydrate vaccines it was not clear whether
short oligosaccharides were sufficient to provide a protective
immune response. Subsequently, pioneering work by Kamerling
in the late 1980s and 1990s showed that short oligosaccharides
are sufficient to induce a protective immune response.28 It is
difficult to generalize howmany RUs of a given CPS are required
as the length of an RUmay vary frommono- to hexasaccharides.
Haemophilus inf luenzae type b (Hib) is an interesting case to
study minimal glycotope length. The bacterium is covered by
the PRP polymer (Figure 8). Licensed glycoconjugate vaccines
are produced from PRP that is isolated from bacterial
fermentation and is often size reduced.15
PRP served as a target for carbohydrate synthesis for 30
years.123−126 Semisynthetic glycoconjugates, containing a
mixture of different length glycotopes produced by polymer-
ization of the RU resulted in the first approved glycoconjugate
vaccine containing a synthetic oligosaccharide hapten and TT
now in routine use in Cuba (Quimi-Hib).48 Though clinically
effective, the oligosaccharide component of Quimi-Hib is a
mixture of oligosaccharides, six to eight RUs on average,
obtained by polycondensation. Synthetic PRP oligosaccharide
antigens of defined length were prepared using a disaccharide
building block and elongation via H-phosphonate chemistry
following a [2 + 2], [4 + 2], [6 + 2], and [8 + 2] synthesis
strategy using orthogonal protecting groups.120 The synthetic
PRP oligosaccharides, similar to natural Hib PRP, were
immobilized on glycan arrays for antibody analysis and coupled
to CRM197 for immunizations. Glycan array analyses revealed
that synthetic PRP oligosaccharides present cross-reactive
epitopes to antibodies raised against isolated PRP. Glycoconju-
gates of PRP oligosaccharides are immunogenic in a rabbit
model (mice are a very poor model to study PRP
immunogenicity), whereby tetrameric PRP is an excellent
starting point for the design of a defined semisynthetic
glycoconjugate Hib vaccine.120
Clostridium dif f icile bacteria are covered with three different
types of polysaccharides termed PS-I, PS-II and PS-III.67,68 Cell-
surface polysaccharide PS-I consists of a pentasaccharide
phosphate RU [ → 4)-α-Rhap-(1 → 3)-β-Glcp-(1 → 4)-[α-
Rhap-(1 → 3)]-α-Glcp-(1 → 2)-α-Glcp-(1 → P] and has been
identified on several C. dif f icile strains.127 PS-I related glycans
are poorly expressed under culture conditions.68 A series of PS-I
related oligosaccharides was prepared to identify the minimally
protective epitope (Figure 9).104 A pentasaccharide-CRM197
conjugate was immunologically evaluated. The glycoconjugate
proved immunogenic in mice and immunoglobulin class-
switching and affinity maturation were observed. Glycan array-
assisted epitope mapping revealed the Rha-(1 → 3)-Glc
disaccharide to be the minimal epitope of the pentasaccharide.
CRM197 glycoconjugates of pentasaccharide 1 as well as
disaccharide 4 are promising vaccine candidates to protect from
C. dif f icile infection; these are currently in further preclinical
evaluation.119
Group A Streptococcus (GAS) bacteria contain a surface
polysaccharide consisting of repeating [ → 3)α-L-Rhap(1 →
2)[β-D-GlcpNAc(1 → 3)]α-L-Rhap(1-]n units (Figure 10).
The helical GAS polysaccharide is conserved and abundantly
expressed on most GAS serotypes (Figure 10a). Purified GAS-
polysaccharide conjugated to tetanus toxoid carrier elicited a
protective immune response in a mouse challenge model.128 A
hexamer of two RUs was reported as core antigenic determinant
believed to be recognized by the human anti-GAS humoral
Figure 8. Structure of the H. inf luenzae type b CPS RU. n = number of
repeating units.
Figure 9. Synthetic PS-I pentasaccharide RU 1 and related glycan substructures 2−6.
Chemical Reviews pubs.acs.org/CR Review
https://doi.org/10.1021/acs.chemrev.0c01210
Chem. Rev. 2021, 121, 3598−3626
3608
immune response.129 A series of synthetic oligosaccharides (7-
10) was used to study the effect of carbohydrate length and
composition on immunogenicity.130 Dodecasaccharide−
CRM197 glycoconjugates (Figure 10b) exposing an immuno-
dominant GlcNAc sugar on the nonreducing terminus elicited
specific IgG titers in mice, comparable to those induced by
CRM197-GAS-PS, while shorter oligosaccharides (7-9) were
less efficacious. Thus, the minimal length epitope was
determined to be a 12-mer. Immunoprotection studies in a
mouse challenge model and opsonophagocytosis in vitro assays
with specific rabbit antisera demonstrated that synthetic
conjugate vaccine candidates have similar efficacy to conjugates
of isolated GAS-polysaccharide.131,132
2.1.2. Glycotope Frameshifts. Vaccines based on isolated
polysaccharides contain long chains of many RUs such that the
nonreducing terminus constitutes only a small part of the overall
glycan. In shorter oligosaccharides, the nonreducing end sugar
makes up a much larger portion of the total glycan. It is this
terminal portion of the glycan that is believed to interact
predominantly with the mammalian immune system. The
nonreducing terminus may play a major role in immunogenicity
albeit not antigenicity and protection. When just a single RU is
the minimal glycotope, the terminal residue may be particularly
important. A RU of four sugars may be depicted in generic terms
as ABCD, BCDA, CDAB or DABC, depending on the
frameshift, and it must be determined by chemical assembly
and immunological testing which is most effective in inducing a
protective immune response.
The search for the optimal frameshift was explored in the
context of oligosaccharide vaccine development for S. pneumo-
niae serotype 8 (SP-8). Four tetrasaccharide frameshifts of the
native SP-8 polysaccharide were prepared by automated glycan
assembly. The availability of all SP-8 frameshift oligosaccharides
was crucial to gain insight into the presence of protective
glycotopes. Yet, a more comprehensive glycan collection was
required to exclude nonprotective glycotopes. In-depth
characterization of protective FS C-directed mAbs revealed a
trisaccharide glycotope that was weakly immunogenic in mice,
but induced a robust antibacterial immune response as a vaccine
antigen in rabbits (Figure 11).133
2.1.3. Sugar Modifications. Carbohydrate modifications
can strongly impact glycan immunogenicity. CPS of bacterial
pathogens are frequently equipped with acetates, pyruvates and
other appendages. Since such modifications are not found on
human glycans, they are believed to be immunogenic and
potentially antigenic and therefore important components of
neoglycoconjugate vaccines.
2.1.3.1. Pyruvate: S. pneumoniae Serotype 4. A pyruvate
molecule can be placed across the (4, 6)-, (3, 4)-, or (2, 3)-
positions. The CPS of the prevalent S. pneumoniae serotype 4
(SP-4) is composed of tetrasaccharide RUs and is included in
existing pneumococcal vaccines. A trans-(2, 3)-linked pyruvate
is present on the SP-4 CPS (Figure 12). The structural antigenic
determinants that are essential for protective immunity,
including the role of the rare and labile cyclic trans-(2,3)
pyruvate ketal modification, were largely unknown. Key
antigenic determinants of SP-4 CPS were determined with the
Figure 10. (a) Structure of the cell-wall polysaccharide RU of Group A Streptococcus and (b) related synthetic oligosaccharides (7−10) utilized for
immunological investigations. n = number of repeating units.
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help of pyruvated and nonpyruvated synthetic RU glycans.134
Glycan arrays revealed which oligosaccharide antigens were
recognized by antibodies in the human reference serum.
Depyruvated SP-4 oligosaccharides were highly immunogenic,
but the resulting antiglycan antibodies showed only limited
binding to the natural CPS present on the bacterial surface.
Glycan array and surface plasmon resonance analysis of murine
polyclonal serum antibodies as well as monoclonal antibodies
showed that terminal sugars are important in directing the
immune responses. The pyruvate modification was a key motif
in designing minimal synthetic carbohydrate vaccines against
SP-4.135
2.1.3.2. 3-Hydroxy-3-methylbutanamide: Bacillus anthra-
cis. A tetrasaccharide found on the glycoprotein BclA on the B.
anthracis cell surface contains three rhamnose residues and an
unusual terminal sugar, 2-O-methyl-4-(3-hydroxy-3-methylbu-
tanamido)-4,6-dideoxy-D-glucopyranose, named anthrose. The
3-hydroxy-3-methylbutanamido side chain of anthrose was
suspected of being immunodominant in this antigen. Synthetic
glycans were screened for their ability to bind antidisaccharide
or antitetrasaccharide mAbs (see also Section 1.3.9, Figure
7).121 A drastic truncation of the chain, produced by reducing 3-
hydroxy-3-methylbutyrate to acetate (compound 17, Figure 13)
resulted in a structure that was not recognized by any mAb.
However, deleting a methyl group within the side chain
(compounds 13 and 14, Figure 13), reduced binding to some
Abs but not to others.121 Similarly, placement of a
trimethylacetyl moiety (compound 15, Figure 13), or deletion
of a 3-hydroxyl group (compound 16, Figure 13) only affected
some mAbs.121
2.1.3.3. Acetates: PNAG. Poly-N-acetylglucosamine (PNAG)
is a surface polysaccharide produced by a broad range of
common pathogens and consists of a β-(1−6)-linked polymer of
N-acetyl-D-glucosamine (GlcNAc) whereby some of the amino
groups lack the acetate substituent. PNAG is produced by
Staphylococci aureus and epidermidis,136 E. coli, Bordetella
pertussis Acinetobacter spp., and Yersinia pestis. Conjugate
vaccines containing highly but not completely deacylated
forms of PNAG are effective at providing protective immunity
in animals. The lack of definition of the chemical composition
and the variability of the vaccine formulation made it difficult for
prior studies to draw final conclusions concerning the vaccine
Figure 11. Differential immune recognition of synthetic SP-8 CPS frameshift oligosaccharides A−D. Glycan microarray analysis of pooled sera from
Pneumovax 23-vaccinated humans (International Reference Serum 007sp), rabbit SP-8 typing serum and a protective murine mAb 28H11 at different
concentrations. Sera were preadsorbed with pneumococcal C-polysaccharide before application. Histograms show mean + SD of eight spots.
Inhibition of antibody binding by preadsorption with native ST8 CPS (10 μg/mL). Statistical analysis (one-tailed, unpaired t test with Welch’s
correction) of eight spots was performed of one out of at least two independent experiments. Asterisks indicate P values: n.s. not significant; **P <
0.005; ***P < 0.001; ****P < 0.0001. Bars depict mean + SD. MFI, mean fluorescence intensity. Reprinted with permission from ref 133. Copyright
2017, American Association for the Advancement of Science.
Figure 12. RU of S. pneumoniae serotype 4 CPS.
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candidate. The position and spacing of deacetylated GlcNac
units was not clear. In order to determine the relative numbers of
glucosamine units and their spacing penta- or nonasaccharide
acetylated oligoglucosamines were compared to the same length
molecules without any acetylation at the amine groups. The fully
acetylated oligosaccharides elicited high titers of nonopsonic
antibodies in mice, whereas the oligosaccharides containing no
acetates elicited no highly active opsonic antibodies in mice and
rabbits. Clearly, the presence of acetate groups is important for
immunogenicity and antigenicity.137 Details concerning the
impact of acetylation content and spacing have yet to be
revealed.
2.1.4. Unstable Epitopes. Modifications of cell-surface
glycans are quite frequently found in bacteria and other
Figure 13. Synthetic glycans (11−23) related to the B. anthracis cell surface tetrasaccharide of BclA used for antibody mapping by microarray
screening. Microarray analysis demonstrates the cross-reactivity of monoclonal antibodies generated against anthrose-rhamnose disaccharide 22
(MTD1-MTD6) and tetrasaccharides 11 and 12 (MTA1-MTA3).
Figure 14. (a) Line and symbol structures of SP-5 CPS RU 24 and synthetic antigen targets (25−27); (b) retrosynthetic analysis of target 25.
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pathogens. These appendages are often key to immunogenicity
and antigenicity (vide supra). Undesired modifications of
glycans can, however, also arise during the purification of a
glycan from biological sources or during its conjugation to a
carrier protein. The reaction of such unstable epitopes may
result in the formation of neo-epitopes and/or the destruction of
epitopes that are required for molecular recognition. Antibody
responses to the novel epitopes may lead to problems such as
autoimmunity or to loss of activity when key epitopes are no
longer recognized.138 The precise modification of glycans can
vary as a result of their isolation process, which defines the
product. Production problems due to product variations
increase manufacturing costs and uncertainties.
2.1.4.1. Ketone: S. pneumoniae Serotype 5. Although SP-5
is the fifth most prevalent serotype, causing invasive pneumo-
coccal disease among young children globally, current
glycoconjugate vaccines are not fully efficacious in preventing
SP-5 infections.16 A change in the CPS glycan structure during
antigen isolation and purification such that the SP-5 antigen no
longer sufficiently resembles the native CPS was suspected of
compromising vaccine efficacy.139 The SP-5 branched penta-
saccharide RU structure (Figure 14)138,140 contains two rare
deoxyamino sugars, the ketoamino sugar 2-acetamido-2,6-
dideoxy-D-xylose-hexos-4-ulose (Sugp) and N-acetyl-L-pneu-
mosamine (L-PneuNAc).
Marketed glycoconjugate vaccines are manufactured from
either native or depolymerized CPS that are, following isolation,
typically coupled to a carrier protein via reductive amination.
The keto group present in the rare sugar Sugp is partially or fully
reduced to form a mixture of SP-5 CPS components and
degrades during glycoconjugate production and leads to
manufacturing issues and decreased immunogenicity.
Defined synthetic antigens resembling the SP-5 CPS RU 24
provided valuable insights into how changes to the natural SP-5
CPS may influence antigen stability and immunogenicity.141
Chemical synthesis provided access to the natural keto
containing RU 24, as well as reduced form oligosaccharides
25−27 (Figure 14) to probe general aspects of vaccine design
relating to the effect of branching, length and the role of unique
sugars like L-PneuNAc and Sugp. CRM197-25 conjugate
formulated with the adjuvant aluminum hydroxide stimulated
more cross-reactive antibodies than CRM197-27 against the
native SP-5 CPS following injection into rabbits. The D-glucose
residue, present in 25, but not in 27, proved vitally important for
antibody recognition and cross-reactivity. The SP-5 epitope
responsible for specificity (l-PneuNAc, D-Glc) differs from the
reducing end sugar (D-FucNAc). The branched pentasaccharide
25 is more immunogenic and a better mimic of the native ST-5
CPS as conjugate CRM197-25 produced CPS specific cross-
reactive antibody titers, in contrast to linear tetrasaccharide
conjugate CRM197-27. Glycan array analyses of human
reference sera and immunization experiments in rabbits
identified the rare aminosugar L-PneuNAc, as well as branching
as key to antibody recognition and avidity. Oligosaccharide 25
containing a secondary alcohol in place of the labile ketone in
native SP-5 CPS 24 resulted in improved antibody titers and
opsonic activity when compared to Prevnar13 that contains
natural SP-5 CPS.141 Themedicinal chemistry approach allowed
for the identification of key epitopes and the replacement of
nonessential, labile entities that create production problems
with closely related, stable functional groups.
Figure 15. Preparation and characterization of a S. pneumoniae serotype 2 (SP-2) CRM197 neoglycoconjugate. (A) Schematic representation of
CRM197-33 conjugate. Hexasaccharide 33was covalently coupled with CRM197 using p-nitrophenyladipate ester as a coupling reagent. (B)MALDI-
TOF analysis was used to determine the average molecular weight of the conjugate; CRM197 was used as a standard. (C) The CRM197-33 conjugate
and CRM197 were resolved with 10% SDS-PAGE and stained with PageBlue protein staining solution. The molecular weight marker is indicated on
the left.
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2.2. Linker Chemistry to Create Glycoconjugates
A small but important piece of the glycoconjugates used as
vaccines is the linker that combines the glycan (synthetic or
isolated) with the carrier (typically a protein). While the
coupling between glycan and carrier has to occur selectively and
efficiently, the resulting linker should be nonimmunogenic. In
traditional glycocconjugate vaccines where isolated glycans are
used, reactive groups present on the polysaccharide are used for
attachment and a host of different points of attachment can be
envisioned. When synthetic oligosaccharides are used, a unique
functional group can be placed for single point attachment.
Typically, the reducing-end of the glycan is equipped with a
linker that contains either an amine or a thiol group. This
functional group can then be selectively coupled to a linker and
to the amine side chains on the carrier protein. A myriad of
different conjugation methods for synthetic oligosaccharides
exist and have been extensively reviewed.142
2.2.1. Attachment via a Terminal Amine. Many site-
selective methods for the attachment of different molecules to
proteins have been developed, recently fueled by programs
developing antibody-drug conjugates. p-Nitrophenyladipate
ester has proven to be an effective coupling reagent to conjugate
glycans to proteins (Figure 15).142−150 The success of the
coupling reaction is assessed by MALDI-TOF mass spectrom-
etry and confirmed by SDS-PAGE.
2.2.2. Attachment via Terminal Thiols. In most cases,
synthetic glycans are equipped with amine-containing linkers
that are used to form adducts with suitable electrophiles. This
conjugation method cannot be used when amines are present in
the glycan antigen to be conjugated. A small, but important class
of bacterial polysaccharides harbor RUs with zwitterionic charge
motifs that typically also contain amine groups. These
zwitterionic polysaccharides (ZPSs) exhibit unique immuno-
modulatory activity and are commonly associated with
commensalism.151−156 ZPSs are the first carbohydrate-only
antigens to induce a T cell-dependent immune response through
a MHC class II dependent pathway.157−161
Thiol-linked glycans have seen limited use for oligosaccharide
conjugation since the thiol moiety is usually introduced at the
very end of a synthesis due to incompatibilities with oxidation
reactions in oligosaccharide assembly. The RU of S. pneumoniae
SP-1 is a ZPS trisaccharide consisting of two D-galacturonic acid
moieties and the rare aminosugar 2-acetamido-4-amino-2,4,6-
trideoxy-D-galactose (D-AAT).162−164 Synthetic SP-1 glycan 34
equipped with thiol linkers enabled the conjugation to glycan
arrays and CRM197 carrier protein (Figure 16).
Marketed glycoconjugate vaccines induce low levels of
functional antibodies against the highly invasive serotype 1
(SP-1), presumably due to obscuring of protective epitopes
during chemical conjugation to carrier proteins. Synthetic
oligosaccharide antigens can incorporate linkers for site-
selective protein conjugation while keeping protective epitopes
intact. An efficacious semisynthetic SP-1 glycoconjugate vaccine
candidate was identified using a panel of synthetic oligosac-
charides that revealed a critical role of the rare aminosugar 2-
acetamido-4-amino-2,4,6-trideoxy-D-galactose (D-AAT). A SP-1
trisaccharide conjugate carrying D-AAT at the nonreducing end
induced a strong antibacterial immune response in rabbits and
outperformed the SP-1 component of the multivalent block-
buster vaccine Prevnar 13.165
2.3. Carriers
Carbohydrates are T-cell independent antigens and fail to
induce a protective immune response in small children.
Therefore, the combination of a carbohydrate B-cell epitope
with a carrier that includes a T-cell epitope is essential to induce
a protective, long-lasting immune response in patients. To date
protein carriers are used exclusively in marketed vaccines but a
host of carriers have been explored as potential components of
next-generation vaccines.
2.3.1. Glycoprotein Carriers. Carrier proteins are isolated
following expression in bioreactors, using well-characterized
bacterial strains.107 A solution of pure protein is obtained after
several chromatography steps and sterile filtration.16 Carrier
proteins such as TT, DT, and CRM197 are well-established in
carbohydrate-based vaccines as they provide the needed T-cell
help for immunological memory. However, the side effects
observed due to the high immunogenicity of commonly used
carriers have prompted the search for alternatives. In addition,
finding nonprotein carrier platforms may alleviate the need of a
cold chain for transportation and storage of vaccines. Not having
to maintain a cold chain would tremendously lower the cost per
dose of vaccine.166
2.3.2. Glycolipid Carriers. Efforts to exploit alternative
methods for antigen presentation aim to utilize the potent helper
functions of invariant natural killer T (iNKT) cells to drive the
production of anticarbohydrate antibodies that protect against
bacterial infection. Activation of iNKT cells is mediated by self-
and exogenous lipid antigens presented by the nonpolymorphic
antigen-presenting molecule CD1d, which is expressed by both
lymphoid lineages (including all B cells) and nonlymphoid
lineages. iNKT cells are “preprimed” in vivo, exhibit a memory
phenotype, and are capable of rapid cytokine release upon
antigen activation. While iNKT cells typically comprise less than
0.1% of circulating T cells in humans, their number exceeds that
of naiv̈e T cells specific for individual peptide antigens. Rather
than responding to peptides, iNKT cells are activated by a
Figure 16. S. pneumoniae serotype 1 (SP-1) is a natural zwitterionic polysaccharide (ZPS) and the synthetic oligosaccharide 34 resembling SP-1 is
conjugated to the carrier protein via a terminal thiol.
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potent lipid agonist known as α-galactosylceramide (α-
GalCer)167 that efficiently stimulates iNKT cells at very low
doses. α-GalCer has been used as an adjuvant in murine models
of disease,168−171 and in human clinical trials.172 Covalent
conjugation of α-GalCer to pneumococcal polysaccharides
promote iNKT cell help for B cell production of the respective
anticarbohydrate antibodies.173
To create a molecule that could provide iNKT cell help for B
cell production of S. pneumoniae polysaccharide-specific anti-
bodies, the S. pneumoniae serotype 4 CPS (Figure 12) was
coupled to the iNKT cell agonist α-GalCer (Figure 17).174 The
CPS-αGC compound was constructed such that B cell
recognition of the CPS moiety was preserved to allow efficient
uptake of the conjugate vaccine by B cells. Minimally destructive
conjugation techniques that preserve the CPS epitopes were
used as a linker that can be processed within B cell lysosomes to
release the α-GalCer moiety to form immunogenic complexes
with CD1d. An amine moiety was placed at the C6 carbon of the
α-GalCer galactose so that lipid immunogenicity was not
disrupted.175 This modified α-GalCer molecule was coupled to
CPS using the widely used activator cyanogen bromide as the
coupling reagent.
Vaccination with CPS-αGC induced the generation of high-
affinity, carbohydrate-specific protective antibodies, the in-
duction of carbohydrate-specific memory B cells, and conferred
full protection against S. pneumoniae infection three months
after the last boost. The high titers of IgG antibodies detected in
sera from vaccinated mice, together with the isolation of mAbs
specific for pneumococcal polysaccharide, demonstrated that
glycoconjugate vaccination efficiently activates carbohydrate-
specific B cells. This approach stimulated polysaccharide-
specific B cells to switch to IgG production and undergo
maturation into long-lived memory B cells. Critically, mice
immunized with the novel vaccine exhibited long-lasting
protection against S. pneumoniae.174
2.3.3. Multivalent Carbohydrate Display. Many new
carrier strategies focus on a multivalent hapten presentation.
Encouraging results in vaccination experiments have been
obtained with oligosaccharide-bound virosomes, liposomes, and
gold nanoparticles (GNP).113−115 The fate of fully synthetic
carriers, such as GNP inside an organism is often unclear. Thus,
both in vivo toxicity and clearance pathways have to be
accurately assessed for these materials.
Self-assembling two-component peptide fibers exposing
Muc1 epitopes were created from peptide Q11 and Muc1
glycopeptides that in turn were assembled by solid phase peptide
synthesis.176 The constructs showed adjuvant-like activity by the
solid aggregates, but the high antibody titers are simply induced
by the multivalent hapten display to B cells.177
The immunomodulatory properties of zwitterionic poly-
saccharides (see section 2.2.2) have been exploited in vaccine
design. Bacteroides f ragilis PSA1, the best studied ZPS
representative, has been used as a carrier for the Tn antigen to
produce an all-carbohydrate cancer vaccine candidate. The Tn-
PSA1 conjugate was found to elicit a specific anti-Tn IgG
response in mice without the need of an adjuvant.178 Antisera
from these mice bound to cancer cells slightly better than
antisera raised against unmodified PSA1.179 Vaccines created
exclusively from carbohydrates are attractive since they do not
require maintenance a cold chain.
3. GLYCOCONJUGATE VACCINE CANDIDATES FROM
ISOLATED AND SYNTHETIC GLYCANS
Almost all currently marketed glycocconjugate vaccines are
based on isolated carbohydrates with the exception of Quimihib,
a Cuban semisynthetic Hib vaccine prepared by chemical
polymerization of a chemically derived building block. With fast
and reliable chemical methods now available to define and
immunologically test minimal glycotopes, the methodology to
establish semisynthetic vaccines is available and has been
employed to identify vaccine candidates for single bacterial
Figure 17. Coupling of S. pneumoniae serotype 4 CPS to the iNKT cell agonist α-GalCer.
Figure 18. Structures of the S. pneumoniae serotypes SP-2, SP-8, and
SP-12F capsular polysaccharide RU.17
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serotypes that can be coformulated to expand the protection of
already existing vaccines or to create novel multivalent vaccines.
3.1. Synthetic Glycoconjugate Vaccine Candidates for
Bacterial Serotypes Without Vaccines
Many deadly pathogens carry unique glycan structures on their
surfaces that may serve as a target for glycoconjugate vaccine
development. Since in some cases, the pathogen is difficult to
culture and in others the isolation of the polysaccharides in pure
form is extremely difficult or completely impossible, the
medicinal chemistry approach offers an attractive alternative.
In this section, candidate vaccines for pathogens or serotypes
where no vaccine is currently available are described.
3.1.1. S. pneumoniae. Licensed polysaccharide conjugate
vaccines cover currently only 13 of the over 90 serotypes of S.
pneumoniae such that nonvaccine serotypes are a major obstacle
to the effective control of invasive pneumococcal disease.
3.1.1.1. SP-2. Serotype 2 is such a nonvaccine serotype that is
the main cause of IPD in many countries in Asia and Middle
America. To prevent IPDs caused by SP-2, the identification of
an effective SP-2 neoglycoconjugate vaccine candidate by the
medicinal chemistry approach was pursued. Glycan microarrays
containing a series of synthetic glycans resembling portions of
the SP-2 CPSRUwere used to screen human and rabbit sera and
identify epitope hits.180 Synthetic hexasaccharide 33 resembling
one RU of SP-2 CPS emerged as a hit from the glycan array
screens (Figure 15). Vaccination with neoglycoconjugates
consisting of hexasaccharide 33 coupled to carrier protein
CRM-197 was found to stimulate a T-cell dependent B-cell
response that induced CPS specific opsonic antibodies in mice,
resulting in killing of encapsulated bacteria by phagocytic
activity. Subcutaneous immunization with neoglycoconjugate
protected mice from intranasal challenge with a highly virulent
SP-2 strain by reducing the bacterial load in lung tissue and
blood.180
3.1.1.2. SP-8. Highly virulent SP-8 causes frequent outbreaks
of invasive disease. Even though SP-8 is part of the
Figure 19. (a) Hexasaccharide RU from two CR-Kp clones isolated during a 2011 hospital outbreak; (b) synthetic hexasaccharide 35 and
substructures 36−40 used for immunological studies.
Chemical Reviews pubs.acs.org/CR Review
https://doi.org/10.1021/acs.chemrev.0c01210
Chem. Rev. 2021, 121, 3598−3626
3615
polysaccharide vaccine Pneumovax 23, it is not included in
conjugate vaccines such as Prevnar 13. Many clinical SP-8
isolates are broadly resistant to antibiotics such that vaccination
to prevent rather than fight SP-8 infections is advisible. The
combination of AGA, glycan microarrays, and mAb reverse
engineering produced semisynthetic glycoconjugate vaccines
against SP-8 that were combined with Prevnar 13 to form
experimental 14-valent vaccines.181
3.1.1.3. SP-12F. The licensed polysaccharide vaccine
Pneumovax 23 contains serotype 12F but is not efficacious in
young children or elderly people, those at highest risk. The
carbohydrate conjugate vaccines Prevanar13 and Synflorix do
not contain SP-12F. Together, SP-12A and SP-12F account for
more than 4% of pneumococcal disease182 and 12F (Figure 18)
dominates with 85%.183 To identify a glycotope that can be
incorporated into a next-generation glycoconjugate vaccine, the
SP-12F hexasaccharide repeat unit (Figure 18) served as a first
step toward a detailed immunological analysis.184
3.1.2. K. pneumoniae. Infections caused by carpabenem-
resistant Klebsiella pneumoniae (CR-Kp) are very problematic
hospital acquired infections, with a 50% average survival rate. At
a time when antibiotics are becoming less effective, no vaccines
to protect from this severe bacterial infection exist. The CPS
surrounding CR-Kp is an attractive starting point to identify
vaccine antigens. A synthesis of the CR-Kp hexasaccharide RU
α-L-Rha-(1 → 4)-[β-D-Gal-(1 → 3)]-α-D-GalA-(1 → 2)-α-L-
Rha-(1 → 2)-α-L-Rha-(1 → 2)-α-L-Rha and related sequences
followed by glycan array studies identified the hexasaccharide as
a starting point for the development of a synthetic
glycoconjugate vaccine.185 Subcutaneous immunization with
synthetic hexasaccharide-CRM197 conjugate resulted in high
titers of cross-reactive antibodies against CR-Kp CPS in mice
and rabbits. Whole cell ELISA revealed surface staining of CR-
Kp strains. Anti-CRM197-35 conjugate antibodies were found
to promote phagocytosis in opsonophagocytic killing assays.
The semisynthetic glycoconjugate is a lead for the development
of a vaccine against a rapidly progressing, deadly bacterium
(Figure 19).185
3.1.3. C. difficile.The hospital acquired infection is currently
treated with the antibiotics that contribute to disease recurrence
in about 20% of patients by disrupting the gut microbiota. As
antibiotics reach their limits, anti-C. dif f icile vaccine candidates
have been pursued. Currently, three candidates are clinically
investigated that induce antitoxin immunity, but do not prevent
bacterial colonization.186 Vaccines targeting the bacterial
surface, in contrast, could reduce the human reservoir and
limit the spread of this emerging pathogen.187C. dif f icile surface-
exposed polysaccharides, PS-I, PS-II, and PS-III, that are
essential for bacterial survival and virulence188 emerged as
targets for colonization-preventing vaccines.67,68 Glycoconju-
gates of isolated PS-II and PS-III were immunogenic in small
animals.189,190 The production of clostridial polysaccharides is
challenging due to their weak and inconsistent expression in
bacterial culture.191,192 Synthetic PS-I,193 PS-II194,195 and PS-
Figure 20. Synthetic oligosaccharide antigens resembling the polysaccharides on the surface of C. dif f icile bacteria that were used as basis for the
development of glycoconjugate vaccine candidates.
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III196 oligosaccharides (Figure 20) were found to be
immunogenic in mice when linked to CRM197 carrier protein.
Very recently, these semisynthetic glycoconjugates were found
to protect from C. dif f icile infections in a murine challenge
model more effectively than an antitoxin vaccine candidate.193
3.1.4. Shigella. While at present, there are no licensed
vaccines available for Shigella, studies in animals and humans
have demonstrated that protection by vaccination is feasible.
With four major species and 50 different serotypes of Shigella,
the development of a broad vaccine may become difficult and
expensive.197 Serum and mucosal antibody responses to Shigella
are predominantly directed against a serotype-specific Shigella
LPS O-antigen. These robust responses lead to the induction of
memory B-cells evidence of their ability to cross-protect against
diverse serotypes is inconclusive.198,199 After early work focusing
on the glycan of S. dysenteriae type 1,200 the first synthetic
oligosaccharide-based conjugate vaccine candidate against the
most endemic Shigella, S. f lexneri serotype 2a (SF-2a), was
developed.201
3.2. Improving Existing Vaccines for Problematic Serotypes
3.2.1. Immunogenicity Problems: S. pneumoniae
Serotype 3. S. pneumoniae serotype 3 (SP-3) causes invasive
pneumococcal infections in adults and is covered by Prevnar13.
The SP-3 glycoconjugates contained in Prevnar13 showed an
atypical immunogenicity and boostability pattern and are of
relatively low efficacy thus resulting in hyporesponsiveness.202
Altered CPS expression, capsule thickness, and an impaired
booster response may all contribute to the low efficacy of ST3
conjugates.203 Prevnar13 is insufficient at limiting acute otitis
media infections caused by SP-3.
Synthetic oligosaccharides based on SP-3 CPS RUs protect
immunized mice against lethal systemic challenge with SP-3
pneumococci via nonmucosal routes.204 A highly immunogenic
SP-3 tetrasaccharide glycoconjugate proved to be immunopro-
tective against experimental pneumonia caused by transnasal
infection with SP-3 strain PN36. Antigenic specificities of anti-
SP-3 antibodies were dissected by glycan arrays displaying
oligosaccharide fragments including the SP-3 CPS RU. An SP-3
oligosaccharide antigen lead for vaccine development was
identified by combining organic synthesis, glycan arrays,
glycoconjugation, in vivo vaccination and challenge experi-
ments.204
3.2.2. Production Problems: S. pneumoniae Serotype
5. S. pneumoniae serotype 5 (SP-5) is the fifth most prevalent
among more than 90 S. pneumoniae serotypes, causing invasive
pneumococcal disease among young children globally.205 A
change in the CPS glycan structure during antigen isolation and
purification such that the SP-5 antigens no longer sufficiently
resemble the native CPS may compromise vaccine efficacy.206
Manufacturing glycoconjugate vaccines such as for ST-5 can be
problematic when CPS contain labile groups (see section
2.1.4.).207
Marketed glycoconjugate vaccines are manufactured from
either native or depolymerized CPS that are typically coupled to
a carrier protein via reductive amination following isolation. The
keto group present in the rare sugar Sugp (Figure 14) is partially
or fully reduced to form a mixture of SP-5 CPS components and
degrades during SP-5 glycoconjugate production. The complex
CPS thus generated is characterized by variable RUs leading to
manufacturing issues and decreased immunogenicity compared
to the native SP-5 CPS.208
Synthetic SP-5 oligosaccharides (25-27) resembling the CPS
RU provided insights into how changes to the natural SP-5 CPS
may influence antigen stability and immunogenicity.141 Total
synthesis provided access not only to the natural keto containing
RU 25, but also oligosaccharides containing the alcohol
products that are the result of the ketone reduction in 25
(Figure 14). Using these synthetic epitopes, vaccine design
considerations relating to the effect of branching, length and the
role of unique sugars like L-PneuNAc and Sugp on overall
immunogenicity and protection were evaluated. The oligosac-
charides related to the SP-5 CPS RU containing a reducing end
linker were fixed on glycan arrays and conjugated CRM197
(Figure 21).
Glycan array analyses of human reference sera and
immunization experiments in rabbits identified the rare
aminosugar L-PneuNAc, as well as branching as key to antibody
recognition and avidity. Oligosaccharide 25 containing a
secondary alcohol in place of the labile ketone in native SP-5
CPS 1 resulted in improved antibody titers and opsonic activity
when compared to Prevnar13 that contains natural SP-5 CPS.141
The medicinal chemistry approach allowed for the identification
of key epitopes and the replacement of nonessential, labile
entities that create production problems with closely related,
stable functional groups. Synthetic chemistry helps to overcome
Figure 21.Microarray with rabbit anti-CRM197-25 and anti-CRM197-
27 conjugates sera. (A) Immunization pattern and sera collection
schedule. Rabbits immunized with CRM197-25 and CRM197-27
conjugates in a prime boost manner on days 0, 14, and 28. Preimmune
and hyperimmune sera collected at different time points from individual
rabbits. (B) Microarray slide printing pattern. (C and D) Microarray
slides incubated with rabbit sera (day 35) raised against CRM197-25
and CRM197-27 conjugates. (E) MFI of cross-reactive spots plotted as
mean ± SD in duplicates. (F) Representation of glycans 25 and 27
immunogenicity and stability moieties.
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vaccine manufacturing problems associated with S. pneumoniae
SP-5 vaccines by increasing stability, immunogenicity, and
protection.141
3.3. Expansion of Marketed Glycoconjugate Vaccines with
Synthetic Glycoconjugates
Current polysaccharide-based S. pneumoniae glycoconjugate
vaccines such as Prevnar13 or Synflorix do not cover all
medically important serotypes and some serotypes that are
included in existing vaccines are either poorly immunogenic or
face production problems. The addition of a semisynthetic
glycoconjugate may expand current formulations or help to
replace serotypes that are not efficiently targeted due to
difficulties during polysaccharide isolation and conjugation.
3.3.1. Addition of Semisynthetic SP-8 Glycoconjugate
to Prevnar 13. S. pneumoniae serotype 8 is not contained in
Prevnar13. To assess whether semisynthetic oligosaccharide-
based SP-8 glycoconjugates are compatible with marketed
polysaccharide-based vaccines, SP-8 glycoconjugate was cofor-
mulated with Prevnar13 to create a 14-valent vaccine.133
Adsorption of tetrasaccharide 22-CRM197 glycoconjugates to
the aluminum phosphate-based Prevnar13 emulsion was
confirmed by flow cytometry, using mAb 1H8 to detect these
glycans (Figure 22). SP-8 glycoconjugates were adsorbed to
Prevnar13 in a dose-dependent manner (Figure 22). SP8
glycoconjugate adsorption did not abrogate adsorption of other
serotypes in Prevnar 13.133
Figure 22.Co-formulation of semisynthetic SP-8 glycoconjugates and Prevnar13. (a) SP-8 glycoconjugates CRM197-41 andCRM197-42were added
to Prevnar13. (b) Rabbits were immunized three times with Prevnar13 with or without coadsorbed CRM197 glycoconjugates. Serum was collected at
day 35. (c) Evaluation of ST8 CPS binding by rabbit sera at day 35. (d) Comparison of SP-8 CPS binding of rabbit sera from different groups. (e)
Comparison of opsonophagocytic killing of SP-8 pneumococci by pooled rabbit sera. (f) Comparison of opsonophagocytic killing by pooled rabbit
sera and human reference serum 007sp at different serum dilutions.
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Immunization of rabbits with two 14-valent coformulations of
Prevnar13 and CRM197-41 or CRM197-42 with a glycan dose
equal to that of most individual serotypes in the commercial
vaccine induced a pronounced immune response against SP8
CPS (Figure 22c,d). Sera of rabbits immunized with the 14-
valent vaccines mediated opsonophagocytic killing of SP-8
pneumococci, in contrast to sera from Prevnar13-immunized
rabbits (Figure 22e,f). Co-formulation with SP-8 glycoconju-
gates did not impair the immunogenicity of other Prevnar13-
specific glycoconjugates, as the immune response of rabbits
toward six Prevnar13-specific CPSs did not decrease. The,
semisynthetic SP-8 glycoconjugates were found to induce a
robust, antibacterial immune response when coformulated with
a multivalent, polysaccharide-based glycoconjugate vaccine.133
3.3.2. Addition of Multiple Semisynthetic Glycoconju-
gates to Prevnar 13. In order to expand the serotype coverage
of marketed Prevnar13 and Synflorix glycocconjugate vaccines a
combination of isolated CPS and synthetic oligosaccharides to
fix problems and expand to serotypes that are currently not
covered. Five synthetic oligosaccharide antigens resembling SP-
2, SP-3, SP-5, SP-8, and SP-14 were conjugated to CRM197
carrier protein to test such an approach (Figure 23). Each of
those glycoconjugates were separately added to Prevnar13 to
create 14-valent vaccines and all five glycoconjugates were also
added to Prevnar13 to fix and expand the existing blockbuster
vaccine. Immunological evaluation of the coformulated vaccine
candidates in rabbits showed encouraging results (Figure 24).181
3.3.3. Fully Synthetic Pentavalent Conjugate S.
pneumoniae Vaccine Candidate. A five-valent vaccine
candidate was created by combining five synthetic oligosac-
charide antigens representing SP-2, SP-3, SP-5, SP-8, and SP-14
were conjugated to CRM197 and formulating them with the
adjuvant alum. The candidate was tested in rabbits and induced
a strong immune response against all of the antigens (Figure
24).181
4. CONCLUSIONS AND PERSPECTIVES
Polysaccharide glycoconjugate vaccines are saving millions of
lives each year by protecting children and adults from bacterial
infections caused by H. inf luenza type b, N. meningitidis, and S.
pneumoniae. From the first insights about the protective power of
isolated polysaccharides and glycoconjugates with protein
carriers in the early 20th century, polysaccharide vaccines
emerged as an effective alternative to antibiotic treatment.
Eventually, these polysaccharide vaccines were replaced by
carbohydrate conjugate vaccines that induced a protective T-cell
mediated response also in infants, the most important risk group
for many infectious diseases. Todayś marketed glycoconjugate
Figure 23. CRM197 conjugates of synthetic oligosaccharide antigens resembling the CPS of S. pneumoniae serotypes 2 (SP-2), 3 (SP-3), 5 (SP-5), 8
(SP-8), and 14 (SP-14).
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vaccines are almost entirely based on isolated glycans obtained
from bacteria. These vaccines are an immense medical and
commercial success but the development of additional such
glycoconjugate vaccines has proven time and resource
consuming.
With the development of automated glycan assembly, access
to defined synthetic oligosaccharides has been greatly
accelerated such that the desired compounds are obtained in
hours or days rather than months of years previously. Quick
access to glycan epitopes enables a medicinal chemistry
approach to glycoconjugate vaccine development. The minimal
protective glycotope of a polysaccharide found on the surface of
a pathogenic bacterium or parasite can be identified by
preparation of a host of glycans resembling the natural glycan.
Using the synthetic glycans, tools such as glycan arrays are
prepared in order to interrogate the human immune response to
pathogens to glean insights into potential motifs that result in a
protective immune response. Immunology, in the interplay with
medicinal chemistry is revealing lead structures for further
development. We are currently beginning to learn the rules
concerning what constitutes an immunogenic and protective
antigen. Many factors including antigen length, terminal
building block, branching, the presence of unusual sugars and
modifications of the glycan are being investigated. While the
process of molecular glycoimmunology is still in the early stages,
it provides the data that will eventually allow for the design of
vaccine antigens rather than the current repetitive trial and error
process.
As basic research into glycoimmunology is ongoing, a number
of synthetic glycotopes that serve as vaccine candidates have
been identified. Semisynthetic glycoconjugates, where a
synthetic glycan has been conjugated to a carrier protein such
as CRM197 that is already a part of marketed vaccines, have
shown great promise in challenge experiments in several animal
Figure 24. In vitro opsonophagocytic activity of a vaccine formulation containing five synthetic oligosaccharide antigens (sPCV5). (a−e) Comparison
of pooled sera from rabbit immunized with sPCV5, Prevnar13+SP-2+SP-8, Synflorix+SP-2+SP-3+SP-8 as well as positive controls Prevnar13 and
Synflorix for opsonophagocytic killing of S. pneumoniae serotypes (A) SP-2, (B) SP-3, (C) SP-5, (D) SP-8, and (E) SP-14. (f and g) Comparison of
antibody titer of pooled serum responsible for 50% killing of bacteria in opsonophagocytic killing assay. IgG titers are expressed as the reciprocal serum
dilution mediating 50% bacterial killing, estimated through nonlinear interpolation of the dilution-killing OPKA data. Human reference serum 007sp
was used as a control. Reprinted with permission from ref 181. Copyright National Academy of Sciences 2018.
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species. Currently, such semisynthetic glycococonjugate vaccine
candidates are in preclinical and clinical development for
bacterial diseases including S. pneumoniae, K. pneumoniae, C.
dif f icile, and Shigella. Fully synthetic glycoconjugates where the
carrier protein has been replaced by a synthetic glycolpid,
peptide, or other carrier are being tested by different laboratories
and show much promise.
In the future, the semisynthetic and fully synthetic vaccine
candidates are expected to either develop into stand-alone
vaccines or to become a part of multivalent vaccines where
isolated and synthetic glycans will be combined. The medicinal
chemistry approach to glycoconjugate vaccine design and
development is complementary to existing approaches based
on isolation of glycans but holds great potential to improve
existing vaccines and develop completely new modes of
protecting humans from our bacterial foes.
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